Therapeutic Uses of Diuresin SR

Diuresin SR is indicated for the treatment of primary arterial hypertension (high blood pressure). Managing hypertension is a critical step in reducing the potential for significant cardiovascular and cerebrovascular events, such as heart attack and stroke. The medication may be utilized as a single therapeutic agent or as a component in a multiple-drug regimen to achieve sustained blood pressure reduction.

Controlling elevated blood pressure with a prescribed regimen is an established method to mitigate long-term cardiovascular risk. Furthermore, the active substance, indapamide, is associated with the capacity to reduce left ventricular hypertrophy (enlargement of the heart's pumping chamber) associated with chronic high blood pressure. This effect contributes to the overall cardiovascular protective benefits of the medication in patients with hypertension.

---

Quick Facts

• Main Indication: Primary arterial hypertension.
• Therapeutic Action: Contributes to blood pressure reduction.
• Associated Benefit: Reduces left ventricular hypertrophy in hypertensive patients.

Regulatory References

1. NIH MedlinePlus guidance

Who can and cannot use Diuresin SR?

This section summarizes the official population eligibility and exclusion criteria for Diuresin SR (Indapamide Sustained Release) as documented in governmental regulatory labeling. The medicine is primarily intended for use in adult patients who do not have specific severe underlying health conditions.

---

Populations That Must Not Use Diuresin SR (Contraindications)

Official regulatory documents define several absolute contraindications for Diuresin SR, meaning the medicine must not be used by individuals who meet these criteria:

• Hypersensitivity: Known allergy or severe reaction to the active substance, indapamide, to other sulfonamides (sulfa drugs), or to any of the product's inactive ingredients (excipients).
• Severe Organ Dysfunction: Individuals with severe renal failure or those with hepatic encephalopathy or other severe impairment of liver function.
• Electrolyte Imbalance: Patients with existing Hypokalaemia (critically low potassium levels in the blood).

---

Other Population Restrictions

Use is also not recommended or established for the following groups:

• Age: Children and adolescents (individuals under 18 years of age) are typically excluded due to a lack of established safety and efficacy data.
• Physiological State: Women who are pregnant or breastfeeding are advised against use.

Diuresin SR (containing Indapamide) interacts with other products, primarily by influencing electrolyte balance and cardiac rhythm.

Documented Interacting Product Categories

Interaction Type	Interacting Products/Classes	Required Constraint
Increased Arrhythmia Risk	Medicines that cause Torsades de Pointes (e.g., certain antiarrhythmics like sotalol and quinidine, certain antipsychotics, and erythromycin IV)	Co-administration is not recommended due to risk of serious ventricular arrhythmia, which is magnified by Indapamide-induced hypokalaemia.
Lithium Toxicity	Lithium preparations	Use requires careful monitoring of plasma lithium levels and dose adjustment, as Indapamide reduces Lithium's renal excretion.
Electrolyte Imbalance	Other potassium-lowering agents (e.g., corticosteroids, stimulant laxatives, other diuretics)	Use requires frequent monitoring of serum potassium and correction of any deficit.
Reduced Efficacy/Renal Risk	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose acetylsalicylic acid	May reduce the product’s blood pressure-lowering effect and increase the risk of acute renal failure, especially in dehydrated patients.

Procedural and Population-Specific Constraints

The official labeling notes that special precautions are required for patients with impaired liver function, as electrolyte imbalance can precipitate hepatic encephalopathy. Dehydration must be corrected prior to administering iodinated contrast media due to the risk of functional renal impairment. For most combinations with anti-hypertensive or cardiac medications, serum electrolyte monitoring and ECG surveillance are mandatory to manage the risk of hypokalaemia and associated cardiac complications. Use with Metformin requires caution due to the risk of lactic acidosis if functional renal impairment occurs.

The mechanism of action for Indapamide (Diuresin SR) is defined by its dual physiological action across two independent systems: the kidney and the vasculature. This combined approach modulates the core processes that affect fluid volume and vascular resistance.

Na+/Cl− Cotransporter Inhibition in the Kidney

Indapamide acts as an inhibitor of the Na+/Cl− cotransporter (NCC) in the distal convoluted tubules of the kidney, preventing the reabsorption of sodium and chloride ions. This molecular blockade leads to increased salt and water excretion, resulting in a reduction in the volume of circulating fluid in the bloodstream.

Direct Modulation of Arterial Smooth Muscle Tone

Indapamide exerts a direct vasodilating effect on the smooth muscle cells lining the arterial walls, independent of its action in the kidney. This action causes the blood vessels to relax and widen, which decreases the Total Peripheral Resistance (TPR) in the circulatory system.

Complementary Mechanisms via Sustained Release

The two distinct mechanisms—reducing fluid volume and lowering vascular resistance—are complementary, providing a dual mechanism for systemic pressure modulation. The sustained-release (SR) formulation maintains a constant drug concentration, which supports the continuous, stable modulation of both the NCC and the vascular smooth muscle.

How to Use Diuresin SR: Administration Guidelines

The usage of Diuresin SR follows standardized protocols to ensure the proper functioning of its Sustained-Release (SR) formulation.

---

Administration Protocol

Diuresin SR is administered by the oral route as a Sustained-Release tablet. The medication is designed for once daily intake, ideally taken in the morning, which supports its use as a long-term treatment for essential hypertension.

Usage Parameter	Standard Instruction
Standard Dosing	Fixed dose of 1.5 mg once daily. Increasing the dose above 1.5 mg is generally not recommended for greater antihypertensive action.
Intake Condition	The tablet may be taken with or without food (irrespective of meals).
Missed Dose	If a dose is missed, the next tablet should be taken at the usual time; a double dose must not be taken to compensate.

---

Procedural and Population Constraints

The integrity of the Sustained-Release tablet is critical for its intended action; therefore, the tablet must be swallowed whole with water. It is explicitly documented that the tablet must not be crushed, broken, or chewed, as this would compromise the release mechanism.

Specific limitations based on patient status are defined for this medication. The use of Diuresin SR is not recommended in the pediatric population due to a lack of sufficient safety data. Furthermore, use is generally restricted for individuals with severe renal impairment or severe hepatic impairment. These instructions define the required method of administration and the populations for whom its use is structurally constrained.

Evidence for use in Primary Arterial Hypertension

The research base for Diuresin SR consists mainly of large-scale, long-term Randomized Controlled Trials (RCTs). These formal studies involved randomly assigning people with high blood pressure to receive either Indapamide (often the sustained-release form), a placebo, or another type of blood pressure medication. The foundation of the evidence base is strengthened by meta-analyses that combine data from many of these trials.

Researchers focused on measuring two main categories of outcomes. The first involved tracking Blood Pressure (BP) Control, examining patterns of systolic and diastolic readings. The second focus was on Hard Cardiovascular Events; these long-term studies monitored the incidence of serious health problems such as fatal and non-fatal stroke, heart attack, and the development of heart failure. Long-term trials reported on the incidence of major cardiovascular events tracked between the agent and comparator groups. However, in many key outcome trials, the agent was studied as a component in a multi-drug regimen, meaning the reported event rates reflect the combination treatment strategy, not the agent used alone.

Evidence Focused on Left Ventricular Hypertrophy (LVH)

Research has explored the agent’s use in patients who have Left Ventricular Hypertrophy (LVH), which is the thickening of the heart’s main pumping chamber. RCTs tracked patients over an intermediate duration, typically 9 to 12 months, comparing the agent against other blood pressure medications. The primary outcome was a change in the Left Ventricular Mass Index (LVMI), a measurement used to track heart muscle size.

What is Still Uncertain about Diuresin SR Research

The evidence contributes to understanding symptom patterns, but several research limitations are noted. The comparative evidence is lacking between the Sustained-Release formulation and the standard formulation regarding a difference in major long-term cardiovascular events. Also, for the associated focus on LVH regression, the follow-up durations were limited, and these studies were not powered to examine a direct link between the observed structural changes and a reduction in long-term stroke or heart attack rates. The results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References

1. Indapamide - NIH MedlinePlus Drug Information
2. Clinical outcomes with indapamide sustained release in the hypertensive patient: a review of the evidence

Common questions about Diuresin SR (FAQ)

Q: What is the main use or indication for Diuresin SR?

Diuresin SR is indicated for treating essential hypertension, which is a medical term for high blood pressure with no identifiable cause. According to the official product information, it is used to lower and control blood pressure in adult patients. This medication is part of a treatment plan managed by a healthcare provider.

Q: How does Diuresin SR work to lower blood pressure?

Diuresin SR contains the active substance Indapamide, which belongs to a class of medicines called diuretics (sometimes called 'water tablets'). Official information states that it works by increasing the amount of salt and water removed from the body by the kidneys. This action helps to relax and widen blood vessels, which in turn contributes to reducing blood pressure.

Q: Can I stop taking Diuresin SR if my blood pressure returns to normal?

Regulatory documents emphasize that hypertension is often a long-term condition requiring continuous treatment. Regulatory information indicates that treatment should not be stopped suddenly, even if blood pressure readings improve. Discontinuing the medication without consulting a healthcare professional may cause blood pressure to rise again.

Q: Is there a specific time of day I should take Diuresin SR?

According to the official product information, Diuresin SR is usually recommended to be taken in the morning. This timing is often suggested to support the medicine's effects throughout the day. Individual patients should follow the specific directions provided by their healthcare professional.

Q: What should I do if I forget to take my dose of Diuresin SR?

Official guidance for a missed dose generally recommends skipping the forgotten dose and continuing with the next scheduled dose at the usual time. It is advised not to take a double dose to compensate for the missed amount. Detailed instructions are always available in the patient information leaflet or from a pharmacist.

Q: How quickly can I expect Diuresin SR to start working?

Studies and official information indicate that Diuresin SR begins to lower blood pressure over the first few weeks of treatment. However, the maximum blood pressure-lowering effect may take several months to be fully achieved. A healthcare professional monitors progress to assess the medication's full effectiveness.

Q: Does Diuresin SR affect blood sugar levels?

Official safety data indicates that this type of medication, like other diuretics, may sometimes affect blood sugar or glucose levels. This effect is noted in the official product information and is typically addressed by healthcare providers, especially for patients with or at risk of diabetes. The need for regular monitoring is determined by a healthcare professional.

Q: Can Diuresin SR be crushed or chewed?

Diuresin SR is a prolonged-release tablet formulation, meaning the medicine is designed to be released slowly over time in the body. Regulatory documents state that the tablets must be swallowed whole with water and should not be crushed, chewed, or broken. Altering the tablet can disrupt the slow-release mechanism and change how the drug works.

Q: Does taking Diuresin SR require any special blood tests?

Official regulatory sources state that regular blood tests may be necessary before and during treatment with Diuresin SR. These tests are typically used to check the levels of potassium and other electrolytes, which can sometimes be affected by diuretics. Monitoring helps ensure the treatment remains safe and effective over time.

How to Store and Dispose of Diuresin SR?

Diuresin SR (Indapamide 1.5 mg prolonged-release tablets) must be stored under conditions specified in the official regulatory labeling to ensure stability and quality.

Storage Requirements

The medicine should be stored at room temperature, typically at or below 25°C or 30°C, and kept from freezing. Protection is required from excessive heat, moisture, and direct light. To maintain the product's integrity, the tablets must remain in the original blister pack and outer carton until administration. As a mandatory safety measure, Diuresin SR must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Diuresin SR must not be discarded through household trash or poured down the drain. Official instructions require returning the medicine to a pharmacist or authorized collection center for appropriate pharmaceutical waste disposal. This procedure helps to protect the environment.